GSK’s Witty Heralds Success Of New Sales Model, Reassures Over Advair

 
• By Anju Ghangurde

GlaxoSmithKline isn't losing too much sleep over imminent generic competition in the US for Advair and CEO Andrew Witty explains why he expects biologics-like economic dynamics for the product. The CEO also outlined the measurable gains of GSK's new model for engaging with healthcare professionals at a media interaction in India.

More from Business

More from Scrip